Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
Consumer BioPharmaceutical Medical Device

Teva Opposes Switching Asthma Drugs, Oral Contraceptives

This article was originally published in The Tan Sheet

  • News

Executive Summary

The firm’s opposition to allowing innovative switches for asthma drugs and oral contraceptives focuses on safety and consumers’ ability to self-select and manage their allergies or reproductive status, but maintains that Plan B One-Step and other emergency contraceptives are appropriate for full OTC status.

Table

View full table

Advertisement

Related Content

Pink Sheet
Asthma Drug Petition Opposes OTC Approach, NSURE Paradigm
Pink Sheet
Asthma Drug Petition Opposes OTC Approach, NSURE Paradigm
HBW Insight
Asthma Drug Petition Opposes OTC Approach, NSURE Paradigm
Pink Sheet
Sanofi’s Nasacort AQ Rx-To-OTC Switch Under FDA Review
Pink Sheet
Rescue Medicine Switch Concept Draws Criticism
Pink Sheet
Birth Control Primed For Switch
Pink Sheet
Teva Plan B OTC Application Fails Political Test After Clearing FDA Hurdle
Pink Sheet
Asthma Treatment OTC Switches Would Face Tough Barriers
Pink Sheet
Teva's Plan B One-Step OTC Application Puts FDA On The Spot
Pink Sheet
Advocates For Switching Birth Control Pill Face Social, Risk Obstacles

Topics

Related Companies

Advertisement
Tags:
Consumer BioPharmaceutical Medical Device
UsernamePublicRestriction

Register

PS105796

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By